SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

NCT04079166 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma
Melanoma (Skin)
Melanoma Stage III
Melanoma Stage IV

Interventions

BIOLOGICAL: SCIB1 or iSCIB1+ DNA vaccine

Sponsor

Scancell Ltd